News

Aboleris Pharma Appoints Seasoned Life-Sciences Executive Philippe Alen as Chief Business Officer

Gosselies, Belgium and Nantes, France, October 30, 2025 /PRNewswire/ -- AbolerIS Pharma (“AbolerIS”), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from autoimmune and inflammatory diseases, today announced the appointment of Philippe Alen as Chief Business Officer (CBO). With over twenty-five years of business development, licensing, M&A and alliance management experience across biotech and big pharma, Philippe will drive Aboleris’ strategic partnerships, financing activities and corporate growth initiatives.

In his new role, Philippe will lead Aboleris’ business development and corporate strategy functions, working closely with the executive leadership team to translate the Company’s deep immunology expertise into collaborations and value-creating transactions.

“Philippe’s proven track record in deal-making and strategic business development is an excellent fit for Aboleris’ ambition to become a key player in inflammatory, autoimmune and degenerative diseases,” said Dr. Ann Meulemans, CEO of Aboleris Pharma. “His leadership will help accelerate our partnerships and financing efforts as we advance our pipeline through the clinic and toward patients in need.”

Philippe holds a PharmD and PhD from the University of Leuven and an MBA from Drexel University, Philadelphia. His broad industry experiences span roles of increasing responsibility at major life-sciences companies including Johnson & Johnson Innovative Medicine, Bayer and Galapagos NV. He has also served on the Board of Directors of Fibrocor Therapeutics. His expertise covers search & evaluation, licensing, M&A, equity investment and alliance management, with experience in therapeutic areas such as infectious diseases, vaccines, cardio-metabolic, women’s health, oncology and immunology.

“I’m thrilled to join Aboleris at this pivotal moment, with ABO21009 rapidly advancing through Phase 1 for the treatment of Rheumatoid Arthritis,” said Philippe Alen, CBO of Aboleris. “The Company’s science, focused on restoring immune tolerance while preserving protective immunity, is uniquely differentiated. I look forward to collaborating with the accomplished team to build meaningful alliances and drive the business forward.”